Mansoor Mirza, MD of Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark discusses clinical trials in ovarian cancer in comparison to the ENGOT-OV16/NOVA Phase III trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer (NCT01847274). According to Dr Mirza, the trials are performed differently. He explains that for a Phase III trial of olaparib, it is only considering the BRCA-mutated population. In the ENGOT-OV16/NOVA trial, the whole population of ovarian cancer patients was included. In the ARIEL series of trials with rucaparib, which is similar to ENGOT-OV16/NOVA, we are still waiting for the results. In Europe, maintenance niraparib therapy is approved for BRCA mutated population but now with the results, he believes all patients can be treated with niraparib regardless of BRCA or HRD mutational status.